Antonin de Fougerolles, previously chief scientific officer at Ablynx NV, has joined Oxford UK-based Evox Therapeutics Ltd as chief executive officer. In this role, he will lead efforts to develop exosome therapeutics for the treatment of disease. In addition to his previous position at Ablynx, Dr de Fougerolles has also held senior research positions at Tolerx Inc and Alnylam Pharmaceuticals Inc. He holds a bachelor’s degree in microbiology and immunology from McGill University in Canada and a PhD in immunology from Harvard University in the US.
Evox Therapeutics announced the appointment on 13 November 2017.
Copyright 2017 Evernow Publishing Ltd